FDA Approves Austedo XR Extended-Release Tablets for Huntington’s Disease


In a significant development for the treatment of Huntington’s Disease (HD), the U.S. Food and Drug Administration (FDA) has granted approval for Austedo XR extended-release tablets. This breakthrough pharmacological solution offers new hope to individuals affected by this devastating neurodegenerative disorder. This blog post will highlight key points surrounding the FDA’s approval of Austedo XR tablets and discuss its potential impact on the lives of HD patients and their families.

Key Points:

1. Understanding Huntington’s Disease:

Huntington’s Disease is a hereditary disorder characterized by the progressive breakdown of nerve cells in the brain, leading to motor function problems, cognitive decline, and psychiatric disturbances. The disease typically manifests in mid-adulthood, causing a significant impact on the individual’s quality of life.

2. Austedo XR: A New Treatment Option:

Austedo XR extended-release tablets offer a ray of hope for individuals living with Huntington’s Disease. The medication, taken orally, works by regulating the levels of a chemical messenger in the brain called dopamine. By reducing dopamine levels, Austedo XR aims to help manage the uncontrolled movements (chorea) associated with HD, thereby improving patient functionality and overall well-being.

3. FDA Approval: A Significant Milestone:

The FDA’s approval of Austedo XR represents a crucial milestone in HD treatment. The decision is based on robust clinical trials demonstrating the drug’s safety and efficacy in reducing chorea symptoms in HD patients. The approval offers new options for patients and their healthcare providers, allowing for a more comprehensive approach to managing the complex challenges posed by Huntington’s Disease.

4. Improving Quality of Life for HD Patients:

The advent of Austedo XR provides an opportunity to significantly enhance the quality of life for individuals living with HD. By mitigating the involuntary movements associated with the disease, patients may experience improved motor control, reduced physical discomfort, and increased independence. This can have a profound impact on daily activities, social interactions, and overall well-being for both the patients and their families.

5. Ongoing Research and Future Prospects:

While the FDA’s approval of Austedo XR is a significant step forward in HD treatment, ongoing research continues to explore new therapeutic approaches for managing the various symptoms of the disease. As researchers strive to uncover additional interventions, the newly approved medication sets the stage for further advancements and combination therapies that may further improve outcomes for HD patients.


The FDA’s approval of Austedo XR extended-release tablets marks a significant breakthrough for individuals afflicted by Huntington’s Disease. With the potential to reduce chorea symptoms and enhance overall functionality, this medication offers a glimmer of hope to patients and their families. By providing an additional treatment option, Austedo XR opens the door to improved quality of life and increased independence for those impacted by this devastating neurodegenerative disorder. As further research and advancements continue in HD treatment, we can anticipate a future with even more promising approaches to managing and someday finding a cure for Huntington’s Disease.